CSIMarket Company Name, Ticker, Competitors, else..
 
Armata Pharmaceuticals Inc   (NYSEAMER: ARMP)
Other Ticker:  
 
 
Price: $1.6800 $0.03 1.763%
Day's High: $1.685 Week Perf: -6.15 %
Day's Low: $ 1.67 30 Day Perf: -21.5 %
Volume (M): 1 52 Wk High: $ 4.25
Volume (M$): $ 2 52 Wk Avg: $2.42
Open: $1.65 52 Wk Low: $1.63



 Market Capitalization (Millions $) 36
 Shares Outstanding (Millions) 21
 Employees 10
 Revenues (TTM) (Millions $) 5
 Net Income (TTM) (Millions $) -19
 Cash Flow (TTM) (Millions $) -4
 Capital Exp. (TTM) (Millions $) 2

Armata Pharmaceuticals Inc
Armata Pharmaceuticals Inc is a biotechnology company that focuses on the discovery and development of bacteriophage-based therapeutics for the treatment of antibiotic-resistant bacterial infections. Bacteriophages are viruses that can specifically target and kill bacterial cells, making them a promising alternative to traditional antibiotics.

The company utilizes its proprietary phage-based platform to identify and engineer phages that can effectively eradicate antibiotic-resistant bacteria. Their goal is to develop phage-based therapies that can address the urgent global health challenge of antibiotic resistance.

Armata Pharmaceuticals Inc has a diverse pipeline of product candidates targeting various bacterial infections, including lung infections caused by Pseudomonas aeruginosa, as well as infections caused by other multidrug-resistant bacteria. They conduct rigorous clinical trials to demonstrate the safety and efficacy of their phage-based therapies.

Through their innovative approach, Armata Pharmaceuticals Inc aims to provide much-needed solutions for patients suffering from antibiotic-resistant infections, for which limited treatment options are currently available.


   Company Address: 5005 McConnell Avenue Los Angeles 90066 CA
   Company Phone Number: 665-2928   Stock Exchange / Ticker: NYSEAMER ARMP


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN   -3.25%    
BIIB   -0.4%    
EXEL   -0.46%    
GILD        3.81% 
MRNA   -4.27%    
NVAX   -4.27%    
• View Complete Report
   



Armata Pharmaceuticals Inc

Armata Pharmaceuticals Inc. Surges on Surprising Revenue Growth

Armata Pharmaceuticals Inc, a Biotechnology & Pharmaceuticals company, has experienced a significant increase in its share price over the past 7 days. The shares rose by 19.17%, bringing the share price to a decline of 26.67% during the second quarter of 2024. Despite this recent surge, the shares are currently trading on the NYSEAMER at 7.7% above its 52-week average.
One of the reasons behind the increase in share price could be the company's announcement of a surge in revenue for the fiscal period ending March 31, 2024. Armata Pharmaceuticals reported a 21.357% increase in revenue, reaching $0.97 million. This growth in revenue is noteworthy considering that many of the company's peers in the Biotechnology & Pharmaceuticals industry saw a decline in their top-line during the same period.
Armata Pharmaceuticals Inc

Armata Pharmaceuticals Inc Sees Stock Surge, But Fails to Turn Profit Despite Revenue Growth

Armata Pharmaceuticals Inc, a Biotechnology & Pharmaceuticals company, has recently experienced a significant increase in stock value over the last five trading days. The stock recorded a solid gain of 6.51%, bringing the share price to 16.13% during the first quarter of 2024. Currently trading on the NYSEAMER, the stock is 47.2% above its 52-week average.
In the fourth quarter of 2023 earnings season, Armata Pharmaceuticals Inc reported widened losses at $-0.55 per share, despite a 45.385% surge in revenue to $1.53 million compared to the same quarter the previous year. This performance stands out in the industry, as many companies are facing challenges with declining revenue and transactions.
Armata Pharmaceuticals Inc

Armata Pharmaceuticals Inc Hit Hard: Dwindling Revenue Amplifies Losses in Q3 2023 Earnings Season

Lower turnover and dwindling revenue have resulted in a higher shortfall for Armata Pharmaceuticals Inc in the third quarter of the 2023 earnings season. The shortfall per share has increased to $-0.86, indicating a decrease in profitability for the company. Additionally, the revenue has also fallen by -8.445% year on year, dropping to $1.23 million.
Comparing these figures to the prior reporting period, where the company achieved revenue of $0.98 million and a bottom line of -$0.17 per share, it is evident that the financial performance has worsened. Armata Pharmaceuticals Inc experienced a net shortfall of $-31.161 million in the third quarter of the 2023 earnings season, which is significantly larger than the $-8.614 million recorded a year ago.
Armata Pharmaceuticals Inc

Armata Pharmaceuticals Inc Reports Alarming -47.955% Drop in Revenue during Fiscal Period Ending June 30, 2023

Armata Pharmaceuticals Inc's recent financial report for the fiscal time-frame ending June 30, 2023, painted a bearish picture for the company. Despite a decrease in the loss per share from $-0.26 to $-0.17 compared to the previous year, the company still reported a loss. Furthermore, although there was an improvement in earnings per share from $-0.40 to $-0.17 in the previous reporting period, this improvement is not substantial enough to suggest a positive trajectory.
The company's revenue also showcased a concerning trend. The revenue declined by a significant -47.955% from $1.88 million to $0.98 million in the comparable financial reporting period, indicating a substantial decrease in demand for Armata Pharmaceuticals Inc's products or services. Although there was a sequential improvement of 23.116% in revenue from $0.80 million, it is not enough to compensate for the overall downward trend.
Armata Pharmaceuticals Inc

Armata Pharmaceuticals Inc Faces Challenging First Quarter with Increasing Net Deficit

Armata Pharmaceuticals Inc reports net deficit increase in Q1 2023
Investors of Armata Pharmaceuticals Inc were presented with disappointing first quarter results on May 10, 2023, with the company reporting an increase in net deficit and a decline in revenue.
According to the company's financial report, for the first quarter of 2023, Armata Pharmaceuticals Inc experienced a deficit per share of $-0.40 per share compared to $-0.30 per share in the same period the previous year. Moreover, the company's net deficit increased to $-14.490 million from $-8.774 million a year ago.






Armata Pharmaceuticals Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com